TITLE

Collaboration with the FDA promising but problematic

PUB. DATE
January 2004
SOURCE
CMAJ: Canadian Medical Association Journal;1/6/2004, Vol. 170 Issue 1, p25
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the reaction of the pharmaceutical industry to an agreement between Canada and the U.S. to share pharmaceutical regulatory information, as of January 2004. Problems that may arise from the agreement; Details of the agreement; Remarks from pharmacology experts.
ACCESSION #
11786684

 

Related Articles

  • Track-and-trace technology slowly progresses. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;12/1/2007, Vol. 64 Issue 23, p2416 

    The article reports on the implementation of pedigree requirements for prescription drug products in California. The law will take effect on January 1, 2009 requiring the pharmaceutical industry to enforce the pedigree requirement for prescription drug products. The Food and Drug Administration...

  • US Regulation of Plant-made Biopharmaceuticals. Berberich, Sharon A.; Devine, Rebecc A. // BioPharm International;Jan2005, Vol. 18 Issue 1, p38 

    Part I. Discusses the U.S. regulation of plant-made biopharmaceuticals. Projections for new and existing biopharmaceutical drugs; History of the plant-made biopharmaceutical industry; Products produced in plants; Role of recombinant organisms in the biomanufacturing industry.

  • Impact of national pharmacare plan studied.  // CMAJ: Canadian Medical Association Journal;11/15/97, Vol. 157 Issue 10, p1338 

    Studies the release of findings on the cost of a fully funded, comprehensive and publicly administered national pharmacare program in Canada. The study by the Pharmaceutical Manufacturers Association of Canada; The cost of the program and the increase to public spending on prescription drugs;...

  • Federal agencies scrutinize pharmaceutical marketing, anticompetitive behavior. Wechsler, Jill // Formulary;Jan2003, Vol. 38 Issue 1, p62 

    Reports on developments related to government policy affecting the pharmaceutical industry in the U.S. as of January 2003. Compliance guidance for pharmaceutical companies issued by the U.S. Department of Health and Human Services in line with proposed Medicare pharmacy benefits for seniors in...

  • Winners and Losers in New Drug Innovation. DiMasi, Joseph A. // Medical Marketing & Media;Sep2001, Vol. 36 Issue 9, p98 

    Focuses on the drug innovations approved since the 1962 amendments to the Federal Food, Drug and Cosmetic Act in the U.S. Extent of innovative output concentration; Leadership position of major companies in research and development; Viability of merger strategy in establishing the market share...

  • Companies indicate support for PhRMA marketing code.  // Medical Marketing & Media;Jun2002, Vol. 37 Issue 6, p18 

    Focuses on the support of pharmaceutical companies for the marketing code of the Pharmaceutical Research and Manufacturers Association. Provision of training programs to educate employees on proper relations with physicians; Changes in the policy of companies; Benefits of the code for sales...

  • FDA overreached its authority in requiring pediatric tests.  // Medical Marketing & Media;Nov2002, Vol. 37 Issue 11, p10 

    Reports on a U.S. federal district's decision that the Food and Drug Administration can (FDA) request but can never require companies to conduct studies of adult drugs on pediatric patients under existing law. Ruling that the FDA overreach its statutory authority under the Pediatric Rule;...

  • HHS guidance reinforces current positions, warns of increased oversight.  // Medical Marketing & Media;Nov2002, Vol. 37 Issue 11, p22 

    Reports on the issuance of Draft Compliance Program Guidance for Pharmaceutical Manufacturers in the United States. Contents of the guidelines; Objectives.

  • Harmonization at home and abroad. Wechsler, Jill // Pharmaceutical Executive;Jun98, Vol. 18 Issue 6, p18 

    Deals with the guidelines for the uniform development of medications in the United States finalized at the International Conference on Harmonization (ICH). Impetus for the harmonization of inspections and enforcement actions of United States Food and Drug Administration; Benefits of adherence...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics